Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy

Open access
Busti, Fabiana, Marchi, Giacomo, Ugolini, Sara, Castagna, Annalisa, Girelli, Domenico · 2018 · Pharmaceuticals

Abstract

Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and overall prognosis. The pathogenesis is complex and typically multifactorial, with iron deficiency (ID) often being a major and potentially treatable contributor. In turn, ID in cancer patients can be due to multiple concurring mechanisms, including bleeding (e.g., in gastrointestinal cancers or after surgery), malnutrition, medications, and hepcidin-driven iron sequestration into macrophages with subsequent iron-restricted erythropoiesis. Indeed, either absolute or functional iron deficiency (AID or FID) can occur. While for absolute ID there is a general consensus regarding the laboratory definition (that is ferritin levels <100 ng/mL ± transferrin saturation (TSAT) <20%), a shared definition of functional ID is still lacking. Current therapeutic options in cancer anemia include iron replacement, erythropoietic stimulating agents (ESAs), and blood transfusions. The latter should be kept to a minimum, because of concerns regarding risks, costs, and limited resources. Iron therapy has proved to be a valid approach to enhance efficacy of ESAs and to reduce transfusion need. Available guidelines focus mainly on patients with chemotherapy-associated anemia, and generally suggest intravenous (IV) iron when AID or FID is present. However, in the case of FID, the upper limit of ferritin in association with TSAT <20% at which iron should be prescribed is a matter of controversy, ranging up to 800 ng/mL. An increasingly recognized indication to IV iron in cancer patients is represented by preoperative anemia in elective oncologic surgery. In this setting, the primary goal of treatment is to decrease the need of blood transfusions in the perioperative period, rather than improving anemia-related symptoms as in chemotherapy-associated anemia. Protocols are mainly based on experiences of Patient Blood Management (PBM) in non-oncologic surgery, but no specific guidelines are available for oncologic surgery. Here we discuss some possible approaches to the management of ID in cancer patients in different clinical settings, based on current guidelines and recommendations, emphasizing the need for further research in the field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph11040094

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 88

  1. Ludwig, 2004, The European cancer anaemia survey (ecas): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, Eur. J. Cancer, 40, 2293, 10.1016/j.ejca.2004.06.019 · DOI · Paper page
  2. Grotto, 2008, Anaemia of cancer: An overview of mechanisms involved in its pathogenesis, Med. Oncol., 25, 12, 10.1007/s12032-007-9000-8 · DOI
  3. Gilreath, 2014, Diagnosis and treatment of cancer-related anemia, Am. J. Hematol., 89, 203, 10.1002/ajh.23628 · DOI · Paper page
  4. Gaspar, 2015, Anemia in malignancies: Pathogenetic and diagnostic considerations, Hematology, 20, 18, 10.1179/1607845414Y.0000000161 · DOI
  5. Adamson, 2008, The anemia of inflammation/malignancy: Mechanisms and management, Hematol. Am. Soc. Hematol. Educ. Program, 2008, 159, 10.1182/asheducation-2008.1.159 · DOI
  6. Rapoport, 2016, Current trends in the management of anaemia in solid tumours and haematological malignancies, Curr. Opin. Support Palliat. Care, 10, 189, 10.1097/SPC.0000000000000209 · DOI
  7. Harper, 2005, Anaemia of cancer: Impact on patient fatigue and long-term outcome, Oncology, 69, 2, 10.1159/000088282 · DOI
  8. Crawford, 2002, Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy, Cancer, 95, 888, 10.1002/cncr.10763 · DOI · Paper page
  9. Caro, 2001, Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review, Cancer, 91, 2214, 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P · DOI · Paper page
  10. Deeb, 2011, Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia, Leuk. Res., 35, 579, 10.1016/j.leukres.2010.10.020 · DOI
  11. Morine, 2011, Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma, Hepatogastroenterology, 58, 1439, 10.5754/hge11156 · DOI
  12. Zheng, S.S., Chen, X.H., Yin, X., and Zhang, B.H. (2013). Prognostic significance of hif-1alpha expression in hepatocellular carcinoma: A meta-analysis. PLoS ONE, 8. · DOI
  13. Harrison, 2002, Impact of tumor hypoxia and anemia on radiation therapy outcomes, Oncologist, 7, 492, 10.1634/theoncologist.7-6-492 · DOI · Paper page
  14. Vaupel, 2004, Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response, Oncologist, 9, 4, 10.1634/theoncologist.9-90005-4 · DOI · Paper page
  15. Cella, 2003, Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes, Ann. Oncol., 14, 511, 10.1093/annonc/mdg167 · DOI
  16. Calabrich, 2011, Management of anemia in cancer patients, Future Oncol., 7, 507, 10.2217/fon.11.24 · DOI
  17. Littlewood, 2001, Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial, J. Clin. Oncol., 19, 2865, 10.1200/JCO.2001.19.11.2865 · DOI · Paper page
  18. Cata, 2013, Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions, Br. J. Anaesth., 110, 690, 10.1093/bja/aet068 · DOI · Paper page
  19. Acheson, 2012, Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: A systematic review and meta-analysis, Ann. Surg., 256, 235, 10.1097/SLA.0b013e31825b35d5 · DOI · Paper page
  20. Liu, L., Wang, Z., Jiang, S., Shao, B., Liu, J., Zhang, S., Zhou, Y., Zhou, Y., and Zhang, Y. (2013). Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: A meta-analysis. PLoS ONE, 8. · DOI
  21. Luan, H., Ye, F., Wu, L., Zhou, Y., and Jiang, J. (2014). Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: A systematic review and a meta-analysis. BMC Surg., 14. · DOI
  22. Sun, 2015, Allogeneic blood transfusion and the prognosis of gastric cancer patients: Systematic review and meta-analysis, Int. J. Surg., 13, 102, 10.1016/j.ijsu.2014.11.044 · DOI
  23. Prescott, 2016, How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology, Cancer Treat Rev., 46, 1, 10.1016/j.ctrv.2016.03.010 · DOI
  24. Boone, 2014, Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients, Gynecol. Oncol., 132, 227, 10.1016/j.ygyno.2013.10.019 · doi:10.1016/j.ygyno.2013.10.019
  25. Alkhalid, 2017, Restrictive transfusion threshold is safe in high-risk patients undergoing brain tumor surgery, Clin. Neurol. Neurosurg., 163, 103, 10.1016/j.clineuro.2017.10.018 · DOI
  26. Vincent, 2015, Transfusion requirements in surgical oncology patients: A prospective, randomized controlled trial, Anesthesiology, 122, 29, 10.1097/ALN.0000000000000511 · DOI · Paper page
  27. Vansteenkiste, 2002, Darbepoetin alfa: Impact on treatment for chemotherapy-induced anemia and considerations in special populations, Oncology, 16, 45
  28. Hedenus, 2003, Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study, Br. J. Haematol., 122, 394, 10.1046/j.1365-2141.2003.04448.x · doi:10.1046/j.1365-2141.2003.04448.x
  29. Bennett, 2008, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia, JAMA, 299, 914, 10.1001/jama.299.8.914 · DOI · Paper page
  30. Samaras, 2008, Risks of venous thromboembolism and mortality associated with erythropoiesis-stimulating agents for the treatment of cancer-associated anemia, Am. J. Hematol. Oncol., 7, 327
  31. Henke, 2003, Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial, Lancet, 362, 1255, 10.1016/S0140-6736(03)14567-9 · DOI · Paper page
  32. Wright, 2007, Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia, J. Clin. Oncol., 25, 1027, 10.1200/JCO.2006.07.1514 · DOI · Paper page
  33. Smith, 2008, Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study, J. Clin. Oncol., 26, 1040, 10.1200/JCO.2007.14.2885 · DOI · Paper page
  34. Farrell, 2004, The erythropoietin receptor and its expression in tumor cells and other tissues, Oncologist, 9, 18, 10.1634/theoncologist.9-90005-18 · DOI · Paper page
  35. Aapro, 2012, Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer, Br. J. Cancer, 106, 1249, 10.1038/bjc.2012.42 · DOI
  36. Aapro, 2015, Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: A meta-analysis, Ann. Oncol., 26, 688, 10.1093/annonc/mdu579 · doi:10.1093/annonc/mdu579
  37. Bennett, 2016, Consensus on the existence of functional erythropoietin receptors on cancer cells, JAMA Oncol., 2, 134, 10.1001/jamaoncol.2015.3940 · doi:10.1001/jamaoncol.2015.3940
  38. Glaspy, 2010, Erythropoiesis-stimulating agents in oncology: A study-level meta-analysis of survival and other safety outcomes, Br. J. Cancer, 102, 301, 10.1038/sj.bjc.6605498 · DOI · Paper page
  39. Ohashi, 2013, Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from japanese randomized, placebo-controlled trials, Cancer Sci., 104, 481, 10.1111/cas.12105 · doi:10.1111/cas.12105
  40. Rizzo, 2010, American society of hematology/american society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer, Blood, 116, 4045, 10.1182/blood-2010-08-300541 · DOI · Paper page
  41. Ludwig, 2013, Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia, Ann. Oncol., 24, 1886, 10.1093/annonc/mdt118 · DOI · Paper page
  42. Aapro, 2012, Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.V. Iron, Ann. Oncol., 23, 1954, 10.1093/annonc/mds112 · DOI · Paper page
  43. Ludwig, 2015, Iron metabolism and iron supplementation in cancer patients, Wien. Klin. Wochenschr., 127, 907, 10.1007/s00508-015-0842-3 · DOI
  44. Ueda, 2017, Role of hepcidin-25 in chronic kidney disease: Anemia and beyond, Curr. Med. Chem., 24, 1417, 10.2174/0929867324666170316120538 · doi:10.2174/0929867324666170316120538
  45. Ueda, N., and Takasawa, K. (2018). Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients, 10. · DOI · Paper page
  46. Aapro, M., Beguin, Y., Bokemeyer, C., Dicato, M., Gascon, P., Glaspy, J., Hofmann, A., Link, H., Littlewood, T., and Ludwig, H. (2018). Management of anaemia and iron deficiency in patients with cancer: Esmo clinical practice guidelines. Ann. Oncol. · DOI
  47. Anand, 2018, Anemia and iron deficiency in heart failure: Current concepts and emerging therapies, Circulation, 138, 80, 10.1161/CIRCULATIONAHA.118.030099 · DOI · Paper page
  48. Steinmetz, 2013, Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia, Ann. Oncol., 24, 475, 10.1093/annonc/mds338 · DOI
  49. Verhaeghe, 2017, The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study, Ann. Gastroenterol., 30, 654
  50. Pfeiffer, 2017, Laboratory methodologies for indicators of iron status: Strengths, limitations, and analytical challenges, Am. J. Clin. Nutr., 106, 1606S, 10.3945/ajcn.117.155887 · DOI · Paper page
  51. Theurl, 2009, Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications, Blood, 113, 5277, 10.1182/blood-2008-12-195651 · DOI · Paper page
  52. Laarakkers, 2011, Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia, Arthritis Rheum., 63, 3672, 10.1002/art.30623 · DOI
  53. Shu, 2015, Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: Pathogenic mechanisms and diagnosis, Eur. J. Haematol., 94, 67, 10.1111/ejh.12402 · DOI
  54. Steensma, 2015, Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia, Blood, 125, 3669, 10.1182/blood-2015-03-636407 · DOI
  55. Hendriks, 2016, Toward worldwide hepcidin assay harmonization: Identification of a commutable secondary reference material, Clin. Chem., 62, 993, 10.1373/clinchem.2016.256768 · DOI
  56. Auerbach, 2004, Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial, J. Clin. Oncol., 22, 1301, 10.1200/JCO.2004.08.119 · DOI · Paper page
  57. Hedenus, 2007, Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study, Leukemia, 21, 627, 10.1038/sj.leu.2404562 · DOI · Paper page
  58. Henry, 2007, Epoetin alfa treatment for patients with chemotherapy-induced anemia, Support Cancer Ther., 4, 78, 10.3816/SCT.2007.n.002 · doi:10.3816/sct.2007.n.002
  59. Bastit, 2008, Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, J. Clin. Oncol., 26, 1611, 10.1200/JCO.2006.10.4620 · DOI · Paper page
  60. Pedrazzoli, 2008, Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha, J. Clin. Oncol., 26, 1619, 10.1200/JCO.2007.12.2051 · DOI · Paper page
  61. Auerbach, 2010, Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia, Am. J. Hematol., 85, 655, 10.1002/ajh.21779 · DOI
  62. Mhaskar, 2016, The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents, Cochrane Database Syst. Rev., 2, CD009624
  63. Vidal, 2013, Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—Systematic review and meta-analysis of randomised controlled trials, Acta Oncol., 52, 18, 10.3109/0284186X.2012.702921 · DOI
  64. Petrelli, 2012, Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials, J. Cancer Res. Clin. Oncol., 138, 179, 10.1007/s00432-011-1072-3 · DOI
  65. Girelli, 2018, Modern iron replacement therapy: Clinical and pathophysiological insights, Int. J. Hematol., 107, 16, 10.1007/s12185-017-2373-3 · DOI · Paper page
  66. Kim, 2007, Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy, Gynecol. Oncol., 105, 199, 10.1016/j.ygyno.2006.11.014 · DOI
  67. Dangsuwan, 2010, Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy, Gynecol. Oncol., 116, 522, 10.1016/j.ygyno.2009.12.004 · DOI
  68. Athibovonsuk, 2013, Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy, Gynecol. Oncol., 131, 679, 10.1016/j.ygyno.2013.09.028 · DOI
  69. Hedenus, 2014, Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy, Med. Oncol., 31, 302, 10.1007/s12032-014-0302-3 · DOI
  70. Coussirou, 2018, Impact of ferric carboxymaltose on the evolution of hemoglobin and ecog performance status in iron-deficient patients with solid tumors: A 3-month follow-up retrospective study, Support Care Cancer, 26, 3827, 10.1007/s00520-018-4250-x · DOI
  71. Clevenger, 2015, Patient blood management to reduce surgical risk, Br. J. Surg., 102, 1325, 10.1002/bjs.9898 · DOI
  72. Munoz, 2015, Pre-operative anaemia: Prevalence, consequences and approaches to management, Blood Transfus., 13, 370
  73. Rineau, 2016, Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: A before-after study, Transfusion, 56, 673, 10.1111/trf.13468 · DOI
  74. Yoo, 2011, Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery, Anesthesiology, 115, 929, 10.1097/ALN.0b013e318232004b · doi:10.1097/aln.0b013e318232004b
  75. Ecker, 2016, Blood transfusion in major abdominal surgery for malignant tumors: A trend analysis using the national surgical quality improvement program, JAMA Surg., 151, 518, 10.1001/jamasurg.2015.5094 · DOI
  76. Dixon, 2009, Blood loss in surgical oncology: Neglected quality indicator?, J. Surg. Oncol., 99, 508, 10.1002/jso.21187 · DOI
  77. Keding, 2018, Patient blood management improves outcome in oncologic surgery, World J. Surg. Oncol., 16, 159, 10.1186/s12957-018-1456-9 · DOI
  78. Borstlap, 2015, Iron therapy for the treatment of preoperative anaemia in patients with colorectal carcinoma: A systematic review, Colorectal Dis., 17, 1044, 10.1111/codi.13110 · DOI
  79. Keeler, 2014, The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer, Colorectal Dis., 16, 794, 10.1111/codi.12683 · DOI
  80. Edwards, 2009, Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery, Br. J. Surg., 96, 1122, 10.1002/bjs.6688 · DOI
  81. Lidder, 2007, Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery—A prospective, randomised, controlled trial, Ann. R. Coll. Surg. Engl., 89, 418, 10.1308/003588407X183364 · doi:10.1308/003588407x183364
  82. Calleja, 2016, Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia, Int. J. Colorectal Dis., 31, 543, 10.1007/s00384-015-2461-x · DOI
  83. Froessler, 2016, The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: A randomized controlled trial, Ann. Surg., 264, 41, 10.1097/SLA.0000000000001646 · DOI · Paper page
  84. Gilreath, 2012, Total dose iron dextran infusion in cancer patients: Is it safe2+?, J. Natl. Compr. Cancer Netw., 10, 669, 10.6004/jnccn.2012.0066 · DOI
  85. Beguin, 2014, Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis—A critical review, Crit. Rev. Oncol. Hematol., 89, 1, 10.1016/j.critrevonc.2013.10.008 · DOI
  86. Jaspers, 2015, Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival, Am. J. Hematol., 90, E197, 10.1002/ajh.24100 · doi:10.1002/ajh.24100
  87. Wilson, 2018, The effect of intravenous iron therapy on long-term survival in anaemic colorectal cancer patients: Results from a matched cohort study, Surg. Oncol., 27, 192, 10.1016/j.suronc.2018.03.005 · DOI
  88. Busti, 2014, Iron deficiency in the elderly population, revisited in the hepcidin era, Front. Pharmacol., 5, 83, 10.3389/fphar.2014.00083 · DOI

Cited by

Metadata

Authors
Busti, F., Marchi, G., Ugolini, S., Castagna, A., & Girelli, D.
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2018-09-30
Volume
11
Issue
4
Pages
94
ISSN
1424-8247 (ISSN-L)
OpenAlex
W2893095850
Cited by
165
References
14
FWCI
7.45
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.